Infectious Diseases

Top Medical News
Nirmatrelvir reduces the risk of long COVID
6 hours ago

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.1

Experimental COVID-19 drug shows promising antiviral efficacy in Asians
Jairia Dela Cruz, 5 days ago
The oral SARS-CoV-2 3C-like protease inhibitor ensitrelvir fumaric acid helps speed up recovery time for COVID-19 symptoms in patients with mild-to-moderate infection, according to the phase III data from the phase II/III SCORPIO-SR study conducted in Asia.
Are Hong Kong doctors the prime culprit behind the growing threat of antimicrobial resistance (AMR)?
5 days ago
A recent study recommends adjusting both loading dosing and maintenance dosing regimens of teicoplanin based on the renal function and serum albumin concentration of patients with methicillin-resistant staphylococcus aureus (MRSA) infection.
COVID-19 impairs sexual function in women
Stephen Padilla, 6 days ago
Being infected with COVID-19 may reduce the sexual function of cisgender women, while having long COVID can worsen the already impaired sexual function as compared to those who do not have long COVID, a study has found. However, the mechanisms as to why these effects occur remain unclear.
Hepatitis E vaccine offers durable protection
26 Feb 2024
Vaccination against hepatitis E appears to provide up to 10 years of protection, with vaccine-induced antibodies persisting for at least 8.5 years, as shown in a study from China.
Bacterial codetection tied to better outcomes in ventilated infants with bronchiolitis
Stephen Padilla, 25 Feb 2024
Bacterial respiratory tract infection normally occurs in infants requiring early intubation in the emergency department (ED) for viral bronchiolitis, according to a study. However, respiratory bacterial codetection appears to shorten the duration of mechanical ventilation (MV) and length of stay (LOS) of these patients in the intensive care unit (ICU).
COVID-19 shots offer durable protection in IBD population
21 Feb 2024
Adults with inflammatory bowel disease (IBD) benefit from COVID-19 vaccination, with its protective effect lasting up to 52 weeks postvaccination even among vulnerable populations such as corticosteroid users and older individuals, according to a study.
Special Reports
Nirmatrelvir reduces the risk of long COVID
05 Mar 2024

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.1

COVID-19, influenza, death, hospital admission, adverse outcome
07 Feb 2024
A comparative analysis has shown that COVID-19 is distinctly more severe than seasonal influenza, with significantly increased long-term risks of adverse health outcomes and burdens.1
Effectiveness of mRNA Vaccines Against Omicron XBB Infection in Singaporean Children Under 5: A Population-Based Cohort Study
22 Jan 2024
Limited data exists on COVID-19 mRNA vaccine effectiveness in children aged 1–4 years, particularly against Omicron subvariants. In a cohort study conducted during Omicron XBB subvariant predominant period in Singapore, completing the primary COVID-19 mRNA vaccine series significantly protected against COVID-19 infection in this age group, with 45.2% and 63.3% vaccine effectiveness in partially and fully vaccinated children, respectively. Vaccine effectiveness was also robust at 74.6% in children with prior COVID-19 infection who received at least one vaccine dose.
COVID-19, nirmatrelvir, ritonavir, mRNA vaccine, Omicron, COPD, CDC, WHO
Dr. Chan Kwok Wai Adrian, Prof. Yang Kuang-Yao, 10 Jan 2024
At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.
Navigating invasive fungal infections in unconventional hosts — insights and strategies
Assoc Prof. Carolina García-Vidal, Dr. Jasmine Chung, 06 Jan 2024

At a recent symposium organized by Pfizer, in collaboration with the Society of Infectious Disease Singapore, A/Prof Carolina García-Vidal, Senior Specialist, Infectious Diseases Department at Hospital Clínic de Barcelona, Spain, shared valuable insights on managing invasive fungal infections (IFIs) in nontraditional hosts. The session was chaired by Dr Jasmine Chung, Senior Consultant and Director of the Antimicrobial Stewardship Unit, Singapore General Hospital.

Real-World Effectiveness of COVID-19 mRNA Vaccines in Patients with Immune-Mediated Inflammatory Diseases (IMID)
14 Dec 2023
Patients with immune-mediated inflammatory diseases face increased COVID-19 risks, but mRNA vaccines offer crucial protection against severe outcomes, including hospitalisation and death, as highlighted by real-world data.
Starting JAK inhibitors in the Asian population based on real-world experience
14 Nov 2023
Dermatologists from Asia shared their clinical experience on the use of Janus kinase (JAK) inhibitors in atopic dermatitis (AD) and discussed approaches towards shared patient and doctor decision-making for treatment with JAK inhibitors. Dr Mark Tang (Mount Alvernia Hospital, Singapore) chaired the virtual meeting, which was attended by local dermatologists.
Conference Reports
Intermittent dosing of dual HIV therapy for HIV disappoints in DUETTO trial
Elvira Manzano, 05 Dec 2023
Four-day-a-week dosing of dual therapy for HIV performs similarly to daily doses in terms of sustaining viral suppression in the DUETTO trial. However, virological failure (VF) and drug resistance rates were higher with the 4-day/week dosing regimen.
COVID-19 infection ups CV risk in people living with HIV
Elvira Manzano, 29 Nov 2023
People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.
PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks
Jairia Dela Cruz, 28 Nov 2023
Viral suppression is maintained through 48 weeks in adults with HIV-1 harbouring drug resistance mutations, who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination pill from a boosted protease inhibitor (bPI) therapy, according to recent data from the phase IV open-label PIBIK trial.
Remdesivir, favipiravir may not be heart-friendly
Audrey Abella, 20 Nov 2023
Remdesivir and favipiravir does not appear to be heart-friendly in patients with COVID-19, according to a study presented at APSR 2023.
Experts share essential updates on COVID-19 vaccines
Elvira Manzano, 20 Nov 2023
SARS-CoV-2 continues to evolve into newer variants. Post-Delta, these variants are generally more highly transmissible and immune-evasive, although not more virulent, said Dr Gregory Poland, Mary Lowell Leary Emeritus Professor of Medicine and director of Mayo Vaccine Research Group, Mayo Clinic in Rochester, Minnesota, US, at IDWeek 2023.
Nirmatrelvir-ritonavir benefits persist against COVID
Elvira Manzano, 07 Nov 2023
Management of most adults with COVID-19, particularly those with mild-to-moderate disease, is increasingly occurring in the outpatient setting due to the availability of effective treatment options. 
Podcast: Professor Flor Munoz discusses the importance of vaccination for pregnant women and children against COVID-19 at IDW
30 Oct 2023
Podcast: Professor Flor Munoz discusses the importance of vaccination for pregnant women and children against COVID-19 at IDWeek 2023